VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma
Status:
Completed
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
VXM01 phase I pilot study in patients with operable recurrence of a glioblastoma to examine
safety, tolerability, immune and biomarker response to the investigational VEGFR-2 DNA
vaccine VXM01